Omeprazole 20 MG Delayed Release Oral Capsule
1 INDICATIONS AND USAGE 1.1 Duodenal Ulcer (adults) Omeprazole delayed-release capsules, USP are indicated for short-term treatment of active duodenal ulcer in adults. Most patients heal within four weeks. Some patients may require an additional four weeks of therapy. Omeprazole delayed-release capsules, USP in combination with clarithromycin and amoxicillin, are indicated for treatment of patients with H. pylori infection and duodenal ulcer disease (active or up to 1-year history) to eradicate H. pylori in adults. Omeprazole delayed-release capsules, USP in combination with clarithromycin are indicated for treatment of patients with H. pylori infection and duodenal ulcer disease to eradicate H. pylori in adults. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence [see CLINICAL STUDIES (14.1) and DOSAGE AND ADMINISTRATION (2)]. Among patients who fail therapy, omeprazole delayed-release capsules, USP with clarithromycin are more likely to be associated with the development of clarithromycin resistance as compared with triple therapy. In patients who fail therapy, susceptibility testing should be done. If resistance to clarithromycin is demonstrated or susceptibility testing is not possible, alternative antimicrobial therapy should be instituted [see MICROBIOLOGY SECTION (12.4)], and the clarithromycin package insert, Microbiology section. 1.2 Gastric Ulcer (adults) Omeprazole delayed-release capsules, USP are indicated for short-term treatment (4 to 8 weeks) of active benign gastric ulcer in adults [see CLINICAL STUDIES (14.2)]. 1.3 Treatment of Gastroesophageal Reflux Disease (GERD) (adults and pediatric patients) Symptomatic GERD Omeprazole delayed-release capsules, USP are indicated for the treatment of heartburn and other symptoms associated with GERD in pediatric patients and adults for up to 4 weeks. Erosive Esophagitis Omeprazole delayed-release capsules, USP are indicated for the short-term treatment (4 to 8 weeks) of erosive esophagitis that has been diagnosed by endoscopy in pediatric patients and adults [see CLINICAL STUDIES (14.4)]. The efficacy of omeprazole delayed-release capsules, USP used for longer than 8 weeks in these patients has not been established. If a patient does not respond to 8 weeks of treatment, an additional 4 weeks of treatment may be given. If there is recurrence of erosive esophagitis or GERD symptoms (e.g., heartburn), additional 4 to 8 week courses of omeprazole may be considered. 1.4 Maintenance of Healing of Erosive Esophagitis (adults and pediatric patients) Omeprazole delayed-release capsules, USP are indicated to maintain healing of erosive esophagitis in pediatric patients and adults. Controlled studies do not extend beyond 12 months [see CLINICAL STUDIES (14.4)]. 1.5 Pathological Hypersecretory Conditions (adults) Omeprazole delayed-release capsules, USP are indicated for the long-term treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine adenomas and systemic mastocytosis) in adults.
redpharm drug, inc.
CAPSULE PINK E 67
DISCLAIMER:
"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."
"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."
"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."
PillSync may earn a commission via links on our site
16 HOW SUPPLIED/STORAGE AND HANDLING Omeprazole Delayed-Release capsules USP, 10 mg are pink/pink size ‘3’ hard gelatin capsule filled with white to off-white enteric-coated granules and imprinted with ‘E’ on pink cap and ‘65’ on pink body with black ink. Bottles of 30 NDC 57237-160-30 Bottles of 100 NDC 57237-160-01 Omeprazole Delayed-Release capsules USP, 20 mg are reddish brown/pink size ‘1’ hard gelatin capsule filled with white to off-white enteric-coated granules and imprinted with ‘E’ on reddish brown cap and ‘67’ on pink body with black ink. Bottles of 30 NDC 57237-161-30 Bottles of 90 NDC 57237-161-90 Bottles of 100 NDC 57237-161-01 Bottles of 1,000 NDC 57237-161-99 Omeprazole Delayed-Release capsules USP, 40 mg are reddish brown/reddish brown size ‘0’ hard gelatin capsule filled with white to off-white enteric-coated granules and imprinted with ‘E’ on reddish brown cap and ‘69’ on reddish brown body with black ink. Bottles of 30 NDC 57237-162-30 Bottles of 90 NDC 57237-162-90 Bottles of 100 NDC 57237-162-01 Storage Store omeprazole delayed-release capsules in a tight container protected from light and moisture. Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].
More pills like CAPSULE E 67